Diligence memo · auto-generated · as of July 2, 2026

TwoStep Therapeutics, Inc.

TwoStep Therapeutics, Inc. looks fair against its niche peers and is active on financing cadence.

SourceRaising on rhythm with a 3.2× step-up on the last round — momentum worth tracking before it's priced in.

Businessfiled

TwoStep Therapeutics, Inc. operates in Pharma, based in SAN CARLOS.

Sub-sector tags: pharma.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

TwoStep Therapeutics, Inc. has raised $28M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).

Largest single filing: $21M on 2026-01-09.

Most recent recorded round closed around 2026-01-09.

Valuation (modeled)modeled

Provath models TwoStep Therapeutics, Inc. at approximately $81M (range $44M–$108M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Fair. Modeled value is 0.84× the median modeled value of Series B Pharma companies in 2025–2027 (8 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.

Financing rhythm & timingmixed

Historic cadence: a new round about every 22 months.

Last raise 6 mo ago; this sector typically re-raises about every 16 months.

Raising on or ahead of the sector's normal rhythm.

The last round stepped up 3.2× from the prior — scaling.

Comparablesmixed

Capital scale ranks ahead of 80% of Pharma peers (310 compared).

Modeled value ranks above 63% of those peers.

Closest niche peers: Juvena Therapeutics, Inc., Alessa Therapeutics, Inc., Amani Therapeutics, Inc., Shenandoah Therapeutics Inc., Atlas Oncology Holdings Inc..

Peoplefiled

4 named people on file across officers, directors and signatories.

Risks & flagsmixed

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.